Terumo Corporation Unsponsored ADR (TRUMY)
Here's Why Momentum in Terumo (TRUMY) Should Keep going
Terumo (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Are You Looking for a Top Momentum Pick? Why Terumo Corp. (TRUMY) is a Great Choice
Does Terumo Corp. (TRUMY) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Terumo (TRUMY) a New Buy Stock
Terumo (TRUMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.
Terumo Corporation (TRUMY) Q4 2024 Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMY) Q4 2024 Results Conference Call May 14, 2024 4:30 AM ET Company Participants Jin Hagimoto - CFO Hikaru Samejima - President, CEO & Director Jin Hagimoto I'm Hagimoto, Terumo's CFO. I would like to present an overview of the year-end financial results for the fiscal year ending March 31, 2024.
